UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Detrusor Underactivity and the Underactive Bladder: A Systematic Review of Preclinical and Clinical Studies

European urology, 2018-11, Vol.74 (5), p.633-643

2018

Link zum Volltext

Verfügbarkeit prüfen

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

Neurourology and urodynamics, 2014-01, Vol.33 (1), p.17-30

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder

European urology, 2013-02, Vol.63 (2), p.296-305

2013

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

European urology, 2020-01, Vol.77 (1), p.119-128

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)

BJU international, 2017-10, Vol.120 (4), p.562-575

2017

Link zum Volltext

Verfügbarkeit prüfen

Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review

European urology, 2019-03, Vol.75 (3), p.464-476

2019

Link zum Volltext

Verfügbarkeit prüfen

Long‐term follow‐up of a multicentre randomised controlled trial comparing tension‐free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women

BJU international, 2015-06, Vol.115 (6), p.968-977

2015

Link zum Volltext

Verfügbarkeit prüfen

Oestradiol-releasing Biodegradable Mesh Stimulates Collagen Production and Angiogenesis: An Approach to Improving Biomaterial Integration in Pelvic Floor Repair

European urology focus, 2019-03, Vol.5 (2), p.280-289

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta‐analysis

BJU international, 2017-11, Vol.120 (5), p.611-622

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase II dose-ranging study of mirabegron in patients with overactive bladder

International Urogynecology Journal, 2013-09, Vol.24 (9), p.1447-1458

2013

Link zum Volltext

Verfügbarkeit prüfen

A proof-of-concept study: Mirabegron, a new therapy for overactive bladder

Neurourology and urodynamics, 2013-11, Vol.32 (8), p.1116-1122

2013

Link zum Volltext

Verfügbarkeit prüfen

The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-Analysis

European urology, 2005-07, Vol.48 (1), p.5-26

2005

Link zum Volltext

Verfügbarkeit prüfen

Are biomechanical properties predictive of the success of prostheses used in stress urinary incontinence and pelvic organ prolapse? A systematic review

Neurourology and urodynamics, 2012-01, Vol.31 (1), p.13-21

2012

Link zum Volltext

Verfügbarkeit prüfen

Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "Overactive bladder"

Neurourology and urodynamics, 2014-07, Vol.33 (S3), p.S6-S13

Chapple, Christopher

2014

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

International journal of clinical practice (Esher), 2017-05, Vol.71 (5), p.e12944-n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

World journal of urology, 2014-12, Vol.32 (6), p.1565-1572

2014

Link zum Volltext

Verfügbarkeit prüfen

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

BJU international, 2005-05, Vol.95 (7), p.993-1001

2005

Link zum Volltext

Verfügbarkeit prüfen

Comparison of fesoterodine and tolterodine in patients with overactive bladder

BJU international, 2008-11, Vol.102 (9), p.1128-1132

2008

Link zum Volltext

Verfügbarkeit prüfen

The placebo effect in overactive bladder syndrome

Nature reviews. Urology, 2011-09, Vol.8 (9), p.495

2011

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment

Urology (Ridgewood, N.J.), 2006-08, Vol.68 (2), p.3-8

2006

Link zum Volltext

Verfügbarkeit prüfen

Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH

World journal of urology, 2015-05, Vol.33 (5), p.697-706

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of tolterodine extended‐release in men with overactive bladder symptoms treated with an α‐blocker: effect of baseline prostate‐specific antigen concentration

BJU international, 2010-11, Vol.106 (9), p.1332-1338

2010

Link zum Volltext

Verfügbarkeit prüfen

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

BJU international, 2005-01, Vol.95 (1), p.81-85

2005

Link zum Volltext

Verfügbarkeit prüfen

It is a great pleasure to introduce to you the fourth edition of this year

Neurourology and urodynamics, 2015-04, Vol.34 (4), p.299-299

Chapple, Christopher

2015

Link zum Volltext

Verfügbarkeit prüfen

Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder

Expert opinion on pharmacotherapy, 2006-12, Vol.7 (17), p.2421-2434

Chapple, Christopher R

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(48)
Life Sciences & Biomedicine
(45)
Science & Technology
(45)
Urology & Nephrology
(39)
Female
(31)
Male
(28)
Middle Aged
(24)
Aged
(22)
Adult
(21)
Urinary Bladder, Overactive - Drug Therapy
(21)
Quality Of Life
(18)
Overactive Bladder
(16)
Double-Blind Method
(15)
Urinary Incontinence
(15)
Urology
(14)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Muscarinic Antagonists - Therapeutic Use
(12)
Acetanilides - Therapeutic Use
(10)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Detrusor Underactivity and the Underactive Bladder: A Systematic Review of Preclinical and Clinical Studies

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)

Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review

Long‐term follow‐up of a multicentre randomised controlled trial comparing tension‐free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women

Oestradiol-releasing Biodegradable Mesh Stimulates Collagen Production and Angiogenesis: An Approach to Improving Biomaterial Integration in Pelvic Floor Repair

Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta‐analysis

A phase II dose-ranging study of mirabegron in patients with overactive bladder

A proof-of-concept study: Mirabegron, a new therapy for overactive bladder

The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-Analysis

Are biomechanical properties predictive of the success of prostheses used in stress urinary incontinence and pelvic organ prolapse? A systematic review

Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "Overactive bladder"

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

Comparison of fesoterodine and tolterodine in patients with overactive bladder

The placebo effect in overactive bladder syndrome

Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment

Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH

Efficacy and safety of tolterodine extended‐release in men with overactive bladder symptoms treated with an α‐blocker: effect of baseline prostate‐specific antigen concentration

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

It is a great pleasure to introduce to you the fourth edition of this year

Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder

Aktive Filter

Suchergebnisse filtern